Evolent Health Inc (NYSE:EVH) – Equities research analysts at SunTrust Banks decreased their FY2017 EPS estimates for shares of Evolent Health in a research note issued on Tuesday. SunTrust Banks analyst S. Draper now expects that the technology company will earn ($0.55) per share for the year, down from their previous estimate of ($0.51). SunTrust Banks currently has a “Buy” rating and a $30.00 target price on the stock. SunTrust Banks also issued estimates for Evolent Health’s Q4 2017 earnings at ($0.02) EPS, FY2018 earnings at ($0.12) EPS and FY2019 earnings at ($0.03) EPS.
Several other equities research analysts also recently commented on the company. Cantor Fitzgerald restated a “buy” rating and set a $30.00 price objective on shares of Evolent Health in a report on Sunday, December 3rd. Leerink Swann set a $25.00 price target on Evolent Health and gave the stock a “buy” rating in a report on Saturday, November 18th. Goldman Sachs Group downgraded Evolent Health from a “conviction-buy” rating to a “buy” rating in a report on Tuesday, November 7th. Robert W. Baird reiterated a “buy” rating and set a $25.00 price target on shares of Evolent Health in a report on Wednesday, November 1st. Finally, Zacks Investment Research upgraded Evolent Health from a “sell” rating to a “hold” rating in a report on Monday, October 9th. Two investment analysts have rated the stock with a sell rating, one has given a hold rating and thirteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus price target of $28.00.
Shares of Evolent Health (NYSE:EVH) opened at $12.90 on Friday. Evolent Health has a 1-year low of $10.30 and a 1-year high of $27.50. The company has a debt-to-equity ratio of 0.11, a quick ratio of 3.34 and a current ratio of 3.34.
Evolent Health (NYSE:EVH) last released its quarterly earnings data on Thursday, November 2nd. The technology company reported ($0.04) EPS for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.08) by $0.04. The firm had revenue of $107.90 million during the quarter, compared to the consensus estimate of $104.49 million. Evolent Health had a negative return on equity of 5.05% and a negative net margin of 15.86%. The company’s quarterly revenue was up 79.2% on a year-over-year basis. During the same quarter in the previous year, the company posted ($0.26) earnings per share.
A number of large investors have recently made changes to their positions in the business. Salem Investment Counselors Inc. grew its stake in Evolent Health by 280.3% in the 3rd quarter. Salem Investment Counselors Inc. now owns 158,705 shares of the technology company’s stock valued at $2,925,000 after purchasing an additional 116,975 shares during the period. Granahan Investment Management Inc. MA grew its stake in Evolent Health by 32.6% in the 3rd quarter. Granahan Investment Management Inc. MA now owns 426,764 shares of the technology company’s stock valued at $7,596,000 after purchasing an additional 104,876 shares during the period. Highbridge Capital Management LLC bought a new position in Evolent Health in the 3rd quarter valued at $366,000. Grandeur Peak Global Advisors LLC grew its stake in Evolent Health by 58.6% in the 3rd quarter. Grandeur Peak Global Advisors LLC now owns 19,625 shares of the technology company’s stock valued at $349,000 after purchasing an additional 7,250 shares during the period. Finally, Sectoral Asset Management Inc grew its stake in Evolent Health by 22.5% in the 3rd quarter. Sectoral Asset Management Inc now owns 652,680 shares of the technology company’s stock valued at $11,618,000 after purchasing an additional 119,868 shares during the period. Hedge funds and other institutional investors own 95.38% of the company’s stock.
COPYRIGHT VIOLATION WARNING: This piece was reported by Dispatch Tribunal and is the property of of Dispatch Tribunal. If you are reading this piece on another domain, it was illegally copied and republished in violation of US and international copyright and trademark legislation. The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/12/15/suntrust-banks-weighs-in-on-evolent-health-incs-fy2017-earnings-evh.html.
Evolent Health Company Profile
Evolent Health, Inc is engaged in healthcare delivery and payment. The Company supports health systems and physician organizations in their migration toward value-based care and population health management. The Company provides an end-to-end, technology-enabled services platform for providers. The Company’s platform, powered by its technology, processes and integrated services, enables providers to migrate their economic orientation from fee-for-service (FFS) reimbursement to payment models that reward value-based payment models.
Receive News & Ratings for Evolent Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Evolent Health and related companies with MarketBeat.com's FREE daily email newsletter.